NO20061953L - Melaninkonsentrerende hormonantagonister - Google Patents

Melaninkonsentrerende hormonantagonister

Info

Publication number
NO20061953L
NO20061953L NO20061953A NO20061953A NO20061953L NO 20061953 L NO20061953 L NO 20061953L NO 20061953 A NO20061953 A NO 20061953A NO 20061953 A NO20061953 A NO 20061953A NO 20061953 L NO20061953 L NO 20061953L
Authority
NO
Norway
Prior art keywords
concentrating hormone
hormone antagonists
melanin concentrating
compounds
appetite
Prior art date
Application number
NO20061953A
Other languages
English (en)
Inventor
Xiufeng Eric Hu
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20061953L publication Critical patent/NO20061953L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse vedrører forbindelser i stand til å tjene som moderatorer av appetitt hos menneske og pattedyr og som sådan tilveiebringer et middel for å redusere kroppsmasse. Forbindelsene ifølge foreliggende oppfinnelse er selektive overfor melaninkonsentrerende hormon, og har ikke de pernisiøse bivirkningene resulterende fra forbindelser som gjensidig påvirker andre appetittrelaterte hjernereseptorer.
NO20061953A 2003-10-01 2006-05-02 Melaninkonsentrerende hormonantagonister NO20061953L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50777303P 2003-10-01 2003-10-01
US53664004P 2004-01-15 2004-01-15
PCT/US2004/031631 WO2005033063A2 (en) 2003-10-01 2004-09-24 Melanin concentrating hormone antagonists

Publications (1)

Publication Number Publication Date
NO20061953L true NO20061953L (no) 2006-06-13

Family

ID=34426018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061953A NO20061953L (no) 2003-10-01 2006-05-02 Melaninkonsentrerende hormonantagonister

Country Status (20)

Country Link
US (1) US7304065B2 (no)
EP (1) EP1667958A2 (no)
JP (1) JP2007508303A (no)
KR (1) KR20060060047A (no)
CN (1) CN101068773A (no)
AR (1) AR045958A1 (no)
AU (1) AU2004278352B2 (no)
BR (1) BRPI0415051A (no)
CA (1) CA2540826A1 (no)
CO (1) CO5690589A2 (no)
IL (1) IL174370A0 (no)
IS (1) IS8360A (no)
MA (1) MA28079A1 (no)
MX (1) MXPA06003654A (no)
NO (1) NO20061953L (no)
PE (1) PE20050475A1 (no)
RU (1) RU2006110272A (no)
SG (1) SG146692A1 (no)
TW (1) TW200526554A (no)
WO (1) WO2005033063A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001160A1 (en) * 2006-06-23 2008-01-03 The Procter & Gamble Company Melanin concentrating hormone antagonists
PT2041093E (pt) * 2006-06-28 2010-06-28 Glaxo Group Ltd Derivados de piperazinilo úteis no tratamento de doenças mediadas pelo receptor gpr38
EP2098509A4 (en) * 2006-10-06 2010-04-07 Taisho Pharmaceutical Co Ltd 1-NAPHTHYLALKYLPIPERIDINDERIVATE
JP2010525069A (ja) * 2007-04-27 2010-07-22 パラテック ファーマシューティカルズ インコーポレイテッド アミノアルキルテトラサイクリン化合物の合成方法および精製方法
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2011524893A (ja) * 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
AR075402A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
WO2011083804A1 (ja) * 2010-01-06 2011-07-14 武田薬品工業株式会社 インドール誘導体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206428A (en) * 1989-11-16 1993-04-27 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthalene derivatives and preparation thereof
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
EP0683782A4 (en) 1993-02-12 1996-03-27 Merck & Co Inc CLASS III ANTIARRHYTHMICS BASED ON SPIRO (2H-1-BENZOPYRANNE-2, 4 'PIPERIDINE).
WO1994027597A1 (en) 1993-05-21 1994-12-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acid angiotensin ii receptor antagonists
EP0763034A1 (en) 1994-05-28 1997-03-19 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
DE4438029A1 (de) * 1994-10-25 1996-05-02 Thomae Gmbh Dr K N.N-disubstituierte Benzocycloalkylamine, ihre Salze mit verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
AU5147196A (en) * 1995-03-27 1996-10-16 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic a gents
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
PT971878E (pt) 1997-02-27 2008-07-08 Takeda Pharmaceutical Compostos de amina, sua produção e utilização como inibidores da produção de amilóide beta
AU5196399A (en) * 1998-08-11 2000-03-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
CN1273451C (zh) 2000-12-22 2006-09-06 先灵公司 哌啶mch拮抗剂及其治疗肥胖症的用途
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
JP2005523237A (ja) 2001-10-01 2005-08-04 大正製薬株式会社 Ｍｃｈ受容体アンタゴニスト
AR036939A1 (es) 2001-10-25 2004-10-13 Schering Corp Antagonistas de la hormona de concentracion de melanina (mch) composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos compuestos, solos o en combinacion, para la elaboracion de un medicamento para el tratamiento de obesidad
WO2003045918A1 (en) 2001-11-26 2003-06-05 Schering Corporation Piperidine-based mch antagonists for treatment of obesity and cns disorders
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
HUP0500034A2 (hu) 2001-12-04 2005-04-28 Schering Corporation N-Aril-N'-(aril-cikloalkil)-karbamid-származékok mint MCH antagonisták és ezeket hatóanyagként tartalmazó gyógyszerkészítmények
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU2003279981A1 (en) * 2002-10-21 2004-05-13 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
CA2521937A1 (en) * 2003-04-10 2004-10-28 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
MA28079A1 (fr) 2006-08-01
CN101068773A (zh) 2007-11-07
CA2540826A1 (en) 2005-04-14
CO5690589A2 (es) 2006-10-31
US7304065B2 (en) 2007-12-04
TW200526554A (en) 2005-08-16
WO2005033063A2 (en) 2005-04-14
PE20050475A1 (es) 2005-10-05
RU2006110272A (ru) 2007-11-10
BRPI0415051A (pt) 2006-11-28
AU2004278352A1 (en) 2005-04-14
EP1667958A2 (en) 2006-06-14
SG146692A1 (en) 2008-10-30
IS8360A (is) 2006-03-17
AR045958A1 (es) 2005-11-16
US20050075324A1 (en) 2005-04-07
KR20060060047A (ko) 2006-06-02
WO2005033063A3 (en) 2007-03-22
MXPA06003654A (es) 2006-06-05
JP2007508303A (ja) 2007-04-05
IL174370A0 (en) 2006-08-01
AU2004278352B2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20061953L (no) Melaninkonsentrerende hormonantagonister
EA200900586A1 (ru) Селективные модуляторы рецепторов эстрогена для лечения вазомоторных симптомов
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
DK1638551T3 (da) Immunosuppressive forbindelser og sammensætninger
CR9291A (es) Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f, y sus usos
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE469895T1 (de) Cgrp-rezeptorantagonisten
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
NZ594140A (en) C5ar antagonists
UA87862C2 (en) 4-benzylidene-piperidin derivatives
ATE399770T1 (de) Tachykininrezeptorantagonisten
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
IL193479A0 (en) Modulators of muscarinic receptors
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
NO20073369L (no) Modulatorer av muskarinreseptorer
DK2257526T3 (da) Spiro(5,5)undecan-derivater
ECSP034860A (es) 5-sustituidas-2-arilpiridinas como moduladores del factor 1 de liberación de corticotropina
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
EA200800573A1 (ru) Аминоарильные сульфонамидные производные как функциональные 5-нтлиганды
EA200801240A1 (ru) Новые способы получения производных циклопропиламида
EA200602081A1 (ru) Пиридиновые производные алкилоксиндолов в качестве агентов, активных в отношении рецептора 5-нт7

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application